Toshihiko Oki

3.8k citations

49 papers · 2.5k indexed · 2 hit papers · h-index 23

Impact in

Immunology top 2%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- Mast cells and histamine
Hematology top 2%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation

Papers in

Hematology 17
- Acute Myeloid Leukemia Research 10
- Hematopoietic Stem Cell Transplantation 4
Immunology 18
- Immune Cell Function and Interaction 10
- Mast cells and histamine 8

Co-authors: Toshio Kitamura Hideaki Nakajima Hidetoshi Kumagai Fumi Shibata Tetsuya Nosaka Jiro Kitaura Kumi Izawa Yoshinori Yamanishi
Journals: Blood (8 papers)Experimental Hematology (4 papers)Journal of Biological Chemistry (4 papers)Leukemia (3 papers)International Journal of Hematology (3 papers)
Partner nations: Japan United States Denmark

In The Last Decade

Toshihiko Oki

48 papers receiving 2.5k citations

Hit Papers

align trajectories log scale

Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics 2003 · 560 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2003 Experimental Hematology
2003 Experimental Hematology

Peers

Countries citing papers authored by Toshihiko Oki

Since Specialization

Citations

This map shows the geographic impact of Toshihiko Oki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshihiko Oki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshihiko Oki more than expected).

Fields of papers citing papers by Toshihiko Oki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshihiko Oki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshihiko Oki. The network helps show where Toshihiko Oki may publish in the future.

Co-authors

The 25 scholars most cited alongside Toshihiko Oki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Toshihiko Oki Line = papers co-authored together Toshihiko Oki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL University of Southern Denmark Research Portal (University of Southern Denmark) ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Safder Saeed, Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, Arthur Vinícius Maciel Dantas, А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, 構成ナーシングビジネス編集室	2024	1
2	Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial Clinical Lymphoma Myeloma & Leukemia ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose Sandoval‐Sus, Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, Arthur Vinícius Maciel Dantas, А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, 構成ナーシングビジネス編集室	2024	2
3	CLL-280 Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial Clinical Lymphoma Myeloma & Leukemia ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose Sandoval‐Sus, Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, Arthur Vinícius Maciel Dantas, А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, 構成ナーシングビジネス編集室	2024	3
4	Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial Blood ·Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raúl Córdoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Charles X. Light, I.A. Kradenova, David Belada	2024	7
5	PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2 Hematological Oncology ·Laurie H. Sehn, Martine E.D. Chamuleau, Georg Lenz, Michael Roost Clausen, Corinne Haïoun, Koji Izutsu, Andrew Davies, Jun Zhu, Toshihiko Oki, Edith Szafer‐Glusman, Knott W.Proch D, Hung‐Yi Chiou, David Ipe, Alexander F. Laszlo, Jian Wu, Gilles Salles	2023	4
6	The Evolving Landscape of Biomarkers in Celiac Disease: Leading the Way to Clinical Development Frontiers in Immunology ·Glennda Smithson, Jenifer Siegelman, Toshihiko Oki, Joseph R. Maxwell, Daniel A. Leffler	2021	14
7	Exit from germinal center to become quiescent memory B cells depends on metabolic reprograming and provision of a survival signal The Journal of Experimental Medicine ·Takeshi Inoue, Ryo Shinnakasu, Taylor Wollek, Wataru Ise, Eiryo Kawakami, Nicolas Sax, Toshihiko Oki, Toshio Kitamura, Kazuo Yamashita, Hidehiro Fukuyama, Tomohiro Kurosaki	2020	61
8	Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance Cell Metabolism ·Nick van Gastel, Jessica B. Spinelli, Azeem Sharda, Amir Schajnovitz, Ninib Baryawno, Catherine Rhee, Toshihiko Oki, Iroda Iminakhunova, J Agerholm-Christensen, Jelena Milosevic, David B. Sykes, Peggy P. Hsu, Matthew G. Vander Heiden, Charles Vidoudez, Sunia A. Trauger, Marcia C. Haigis, David T. Scadden	2020	94
9	Untargeted Metabolomics Identifies Glutamine Metabolism As a Driver of Chemoresistance in Acute Myeloid Leukemia Blood ·Nick van Gastel, Amir Schajnovitz, Charles Vidoudez, Toshihiko Oki, Azeem Sharda, Sunia A. Trauger, David T. Scadden	2017	2
10	A Genome-Wide, In Vivo, Dropout CRISPR Screen in Acute Myeloid Leukemia Identifies an Essential Role for Beta-Galactosylation in Leukemic Cell Homing Blood ·François Mercier, Jiantao Shi, David B. Sykes, Elizabeth R. Miller, Toshihiko Oki, 進藤英世, Xiaojing Yan, Youmna Kfoury, Dongjun Lee, John G. Doench, Franziska Michor, David T. Scadden	2017	2
11	Epigenetic Memory Underlies Cell-Autonomous Heterogeneous Behavior of Hematopoietic Stem Cells Cell ·Vionnie W.C. Yu, Rushdia Z. Yusuf, Toshihiko Oki, Juwell W. Wu, Borja Sáez, Xin Wang, Colleen Cook, Ninib Baryawno, Michael J. Ziller, Eunjung Lee, Hongcang Gu, Alexander Meissner, Charles P. Lin, Peter V. Kharchenko, David T. Scadden	2016	145
12	Hes1 upregulation contributes to the development of FIP1L1-PDGRA–positive leukemia in blast crisis Experimental Hematology ·Tomoyuki Uchida, Jiro Kitaura, Fumio Nakahara, Katsuhiro Togami, Daichi Inoue, Akie Maehara, Koutarou Nishimura, Kimihito C. Kawabata, Noriko Doki, Kazuhiko Kakihana, Kosuke Yoshioka, Kumi Izawa, Toshihiko Oki, Akiko Sada, Yuka Harada, Kazuteru Ohashi, Yoshio Katayama, Toshimitsu Matsui, Hironori Harada, Toshio Kitamura	2014	6
13	Human CD300C Delivers an Fc Receptor-γ-dependent Activating Signal in Mast Cells and Monocytes and Differs from CD300A in Ligand Recognition Journal of Biological Chemistry ·Mariko Takahashi, Kumi Izawa, Jun‐ichi Kashiwakura, Yoshinori Yamanishi, Yutaka Enomoto, Ayako Kaitani, Akie Maehara, Masamichi Isobe, Shin‐ichi Ito, Toshihiro Matsukawa, Fumio Nakahara, Toshihiko Oki, Masunori Kajikawa, Chisei Ra, Yoshimichi Okayama, Toshio Kitamura, Jiro Kitaura	2013	26
14	Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice International Journal of Hematology ·Yuki Kagiyama, Jiro Kitaura, Katsuhiro Togami, Tomoyuki Uchida, Daichi Inoue, Toshihiro Matsukawa, Kumi Izawa, Kimihito C. Kawabata, Yukiko Komeno, Toshihiko Oki, Fumio Nakahara, Katsuaki Sato, Hiroyuki Aburatani, Toshio Kitamura	2012	6
15	Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis Leukemia ·Toshihiko Oki, Jiro Kitaura, Naoko Watanabe‐Okochi, Koutarou Nishimura, Akie Maehara, T Uchida, Yukiko Komeno, Fumio Nakahara, Yuka Harada, Takashi Sonoki, Hironori Harada, Toshio Kitamura	2011	27
16	Characterization of Leukocyte Mono-immunoglobulin-like Receptor 7 (LMIR7)/CLM-3 as an Activating Receptor Journal of Biological Chemistry ·Yutaka Enomoto, Yoshinori Yamanishi, Kumi Izawa, Ayako Kaitani, Mariko Takahashi, Akie Maehara, Toshihiko Oki, Pa Saffiong Kebbeh, Masunori Kajikawa, Toshiyuki Takai, Toshio Kitamura, Jiro Kitaura	2010	15
17	Evidence That Integrin αIIbβ3-dependent Interaction of Mast Cells with Fibrinogen Exacerbates Chronic Inflammation Journal of Biological Chemistry ·Toshihiko Oki, Koji Eto, Kumi Izawa, Yoshinori Yamanishi, Naoki Inagaki, Jon Frampton, Toshio Kitamura, Jiro Kitaura	2009	11
18	Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD Leukemia ·Lu Yang, Jiro Kitaura, Toshihiko Oki, Yukiko Komeno, Katsutoshi Ozaki, Mari Kiyono, Hidetoshi Kumagai, Hideaki Nakajima, Tetsuya Nosaka, Hiroyuki Aburatani, Toshio Kitamura	2007	21
19	Integrin αIIbβ3 Induces the Adhesion and Activation of Mast Cells through Interaction with Fibrinogen The Journal of Immunology ·Toshihiko Oki, Jiro Kitaura, Koji Eto, Lu Yang, Mari Maeda‐Yamamoto, Naoki Inagaki, Hiroichi Nagai, Yoshinori Yamanishi, Yanbin Jiang, Hidetoshi Kumagai, Toshio Kitamura	2006	35
20	Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics Experimental Hematology ·Toshio Kitamura, 宮本真理子, Fumi Shibata, Toshihiko Oki, Hideaki Nakajima, Tetsuya Nosaka, Hidetoshi Kumagai Hit paper breakdown →	2003	591

About Toshihiko Oki

Toshihiko Oki is a scholar working on Hematology, Immunology, Genetics, Immunology and Allergy and Cancer Research, having authored 49 papers that have together received 2.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (10 papers), Immune Cell Function and Interaction (10 papers), Mast cells and histamine (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), CRISPR and Genetic Engineering (6 papers), Hematopoietic Stem Cell Transplantation (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). The work is most often cited by research in Immunology (956 citations), Hematology (458 citations), Immunology and Allergy (123 citations), Molecular Biology (1.2k citations) and Genetics (167 citations). Toshihiko Oki has collaborated with scholars based in Japan, United States and Denmark. Frequent co-authors include Toshio Kitamura, Hideaki Nakajima, Hidetoshi Kumagai, Fumi Shibata, Tetsuya Nosaka, Jiro Kitaura, Kumi Izawa, Yoshinori Yamanishi, Akie Maehara and Hiroshi Kiyonari. Their work appears in journals such as Blood, Experimental Hematology, Journal of Biological Chemistry, Leukemia and International Journal of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact